This study is looking at whether a supplement called beta-hydroxybutyrate (BHB) can help people with Crohn's disease who are starting a new treatment. Researchers want to see if taking BHB capsules for 4 weeks is practical and acceptable for patients. They also want to find out if BHB might reduce inflammation and change the types of bacteria in the gut. You could join if you are at least 18 years old, have a confirmed diagnosis of Crohn's disease with active symptoms (like a fecal calprotectin level above 250 µg/g or active disease seen on endoscopy), and are starting a new therapy for your Crohn's. This study aims to enroll 20 participants.

Study design

This is an open-label pilot study, meaning you and the researchers will know you are receiving the beta-hydroxybutyrate supplement. It is designed to see if the treatment is feasible for patients with Crohn's disease.

What's involved

You would take 3 capsules of beta-hydroxybutyrate, three times a day, for 4 weeks. You would also complete a 24-hour food recall questionnaire and provide blood and stool samples twice: at the beginning and after 4 weeks.

Compensation

Not stated in the trial record.

Follow-up

The study will track certain aspects, like your adherence to the intervention, for 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.